Filing Flows › Regeneron Pharmaceuticals (REGN) › Operating margin
Regeneron Pharmaceuticals (REGN) operating margin by quarter
Regeneron Pharmaceuticals' operating margin was 40.0% in Q3 2026 (third quarter 2026), +9.9 pts from Q2 2026. Over the last 7 quarters it ranged from 17.8% (Q1 2026) to 40.0% (Q3 2026).
| Quarter | Operating margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 40.0% | +9.9 pts | +12.7 pts |
| Q2 2026 | 30.1% | +12.3 pts | +0.8 pts |
| Q1 2026 | 17.8% | -4.8 pts | -1.7 pts |
| Q4 2025 | 22.7% | -4.7 pts | — |
| Q3 2025 | 27.3% | -2.0 pts | — |
| Q2 2025 | 29.4% | +9.8 pts | — |
| Q1 2025 | 19.5% | — | — |
Q3 2026 at a glance
Regeneron Pharmaceuticals, Q3 2026: revenue $5.1B (+36% year over year), operating margin 40.0%, net earnings $1.9B, operating cash flow $1.8B. The chart follows the revenue to costs, profit and cash.
Questions
What is Regeneron Pharmaceuticals' operating margin?
Regeneron Pharmaceuticals' operating margin was 40.0% in Q3 2026 (third quarter 2026), +9.9 pts from Q2 2026.
How has Regeneron Pharmaceuticals' operating margin changed?
Over the last 7 quarters it ranged from 17.8% (Q1 2026) to 40.0% (Q3 2026).
Q3 2026 results → · How Regeneron Pharmaceuticals makes money →